Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Grethel Perez Meek, DO
Advertisement
Articles by Grethel Perez Meek, DO
Advertisement
Latest Updated Articles
Phase 3 Trials Examine Gantenerumab for Early Alzheimer DiseasePublished: February 20th 2024 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases
2
Preliminary Report on Dangers of AI Chatbots
3
The Trial of ChatGPT: What Psychiatrists Need to Know About AI, Suicide, and the Law
4
6 Helpful Pearls From the International Guidelines for Algorithmic Treatment of Schizophrenia
5
